|
Mon, 06/17/2024 - 12:04 |
Inhibikase Therapeutics Completes Enrollment of the Phase 2 201 Trial Evaluating Risvodetinib in Untreated Parkinsons Disease |
Inhibikase Ther... |
|
Wed, 06/05/2024 - 11:22 |
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs |
Inhibikase Ther... |
|
Wed, 05/15/2024 - 11:04 |
Novartis highlights pioneering innovation in CML with data from Scemblix Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA |
Novartis |
|
Fri, 05/10/2024 - 14:48 |
Novartis receives FDA Breakthrough Therapy designation for Scemblix in 1L CML |
Novartis |
|
Fri, 05/10/2024 - 04:58 |
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension |
Inhibikase Ther... |
|
Thu, 02/29/2024 - 03:52 |
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro |
Inhibikase Ther... |
|
Wed, 02/07/2024 - 17:48 |
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers |
Inhibikase Ther... |
|
Thu, 02/01/2024 - 13:32 |
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib |
Inhibikase Ther... |
|
Mon, 12/12/2022 - 12:59 |
Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro |
Inhibikase Ther... |
|
Tue, 11/22/2022 - 08:57 |
Inhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference |
Inhibikase Ther... |
|
Fri, 08/26/2022 - 16:15 |
Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia |
Inhibikase Ther... |
|
Tue, 08/23/2022 - 06:01 |
Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease |
Inhibikase Ther... |
|
Wed, 03/23/2022 - 07:45 |
Inhibikase Therapeutics to Participate in the Maxim Group 2022 Virtual Growth Conference |
Inhibikase Ther... |
|
Mon, 10/18/2021 - 23:44 |
Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009 |
Inhibikase Ther... |
|
Mon, 07/26/2021 - 14:58 |
Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients |
Inhibikase Ther... |
|
Fri, 07/24/2020 - 06:03 |
Blueprint Medicines Receives Positive CHMP Opinion for Avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors |
Blueprint Medicines |
|
Fri, 05/15/2020 - 17:04 |
FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors |
FDA |
|
Mon, 04/20/2020 - 06:18 |
Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients |
Novartis |
|
Wed, 01/08/2020 - 21:11 |
Blueprint Medicines Announces FDA Approval of AYVAKIT (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor |
Blueprint Medicines |
|
Fri, 01/03/2020 - 14:32 |
Fox Chase Team Awarded Grant to Research Rare GI Tumors |
Fox Chase |
|
Tue, 11/12/2019 - 11:14 |
Intermountain Cancer Care is Praised by Renowned Oncology Researcher and a New Cancer Answers Hotline is launched |
Intermountain H... |
|
Tue, 10/15/2019 - 10:46 |
Antibody eradicates leukemia stem cells |
UCLA |
|
Tue, 10/08/2019 - 23:43 |
Salk scientist Tony Hunter receives National Cancer Institute Outstanding Investigator Award |
Salk Institute |
|
Thu, 09/12/2019 - 07:17 |
Lineage Plasticity in Prostate Cancer |
RockefellerUniv... |
|
Thu, 07/18/2019 - 17:03 |
Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application for Avapritinib for the Treatment of PDGFR D842V Mutant GIST and Fourth-Line GIST |
Blueprint Medicines |
